

## Index

- AAADC  
 activity  
   assayed with [<sup>3</sup>H]DOPA  
     in living rat brain,  
     50, 52  
   measured by FDOPA  
     PET, 65  
   pharmacological  
     modulation of, 52,  
     53, 62, 69–70  
   regulation by second  
     messengers, 49  
   true magnitude of, 67  
 inhibition by NSD 1015, 30  
 kinetic properties and  
   substrate specificity  
   in vitro, 46, 47  
 substrates for PET studies  
   of, 68  
 transcriptional  
   regulation, 48
- Acetylcholine  
 striatal interneurons, 15
- acidic metabolites  
 efflux from brain  
   blockade by  
     haloperidol, 90  
   microdialysis study of  
     kinetics, 93
- rate for DOPAC, 91  
 sulfoconjugation in brain,  
   8, 92–94
- adenylate cyclase,  
 and regulation  
   of TH activity,  
   16, 26
- ADHD  
 D<sub>2</sub>-like dopamine  
   receptors, 209–210  
 DAT-PET and SPET studies  
   of, 156  
 FDOPA-PET results  
   in, 70
- aging  
 D<sub>1</sub>-like dopamine receptor  
   binding, 170, 171  
 D<sub>2</sub>-like dopamine receptor  
   binding, 194  
 DAT binding changes, 139,  
   145, 146, 149  
 [<sup>11</sup>C]DTBZ-PET studies of,  
   116, 119, 120  
 elimination rate constant of  
   [<sup>18</sup>F]fluorodopamine,  
   67  
 FDOPA utilization in  
   striatum, 61, 71  
 MAO activity, 103
- Alcoholism, and  
 D<sub>2</sub>-like dopamine  
   receptors, 196, 204  
 DAT-PET, 157  
 [<sup>11</sup>C]DTBZ-PET, 121  
 FDOPA-PET, 76
- Alzheimer's dementia, and  
 D<sub>1</sub>-like dopamine  
   receptors, 172  
 D<sub>2</sub>-like dopamine  
   receptors, 198  
 DAT-PET, 155
- amphetamines  
 blockade at DAT,  
   general mechanism,  
   9, 128  
 blockade of VMAT2, 114  
 D<sub>1</sub>-like dopamine receptor  
   binding,  
   invulnerability to,  
   173  
 [<sup>11</sup>C]DTBZ PET, 121  
 effects of chronic use on  
   DAT, 158  
 effects on D<sub>2</sub>-like receptor  
   binding, and, 183,  
   184, 189, 205  
 sensitization of,  
   207–208, 223

## 332 Index

- amphetamines (cont.)  
 sensitization of, 213  
 interstitial dopamine  
 levels increased by,  
 124, 129  
 rewarding properties of,  
 16, 207
- AMPT  
 blockade of TH by, 35  
 D<sub>2</sub>-like receptor binding  
 after, 206  
 evidence for quantal release  
 of dopamine, 128  
 potential tracer for TH  
 activity, 40
- anaesthesia, effects on  
 dopamine receptor  
 binding, 182, 204, 214
- anticonvulsants, and D<sub>2</sub>-like  
 dopamine receptor  
 binding, 213
- antipsychotic, atypical  
 occupancy at D<sub>2</sub>-like  
 receptors in cortex,  
 201  
 possible action at  
 dopamine D<sub>4</sub>  
 receptors, 163
- antipsychotic medication,  
 typical  
 activation of AAADC  
 by, 49  
 activation of TH by, 22, 25,  
 30, 39  
 benzamides, binding  
 kinetics in vivo,  
 175, 182  
 effects on acidic metabolite  
 transport, 91  
 effects on dopamine  
 turnover evoked  
 by, 87  
 modulation of FDOPA  
 uptake by, 62
- antizyme  
 control of amino acid  
 decarboxylases  
 by, 49
- Aphakia mice, 13
- apomorphine  
 inhibition of TH by, 27, 30
- aromatic amino acid  
 decarboxylase, *see*  
 AAADC
- aryl-sulfotransferase  
 biochemistry of, 81, 83  
 conjugation of acidic  
 metabolites by, 92
- asymmetry  
 dopamine D<sub>2</sub>-like receptors  
 and, 196, 208–209  
 dopamine markers in  
 hemi-parkinsonism  
 and, 59, 60, 150, 152
- attention deficit hyperactivity  
 disorder, *see* ADHD
- autoreceptors  
 control of TH activity by, 7,  
 22, 24–26, 30, 32–33,  
 39, 44  
 modulation of AAADC  
 activity, –53, 49, 52,  
 62, 70  
 predominance in  
 substantia nigra, 201
- Ayahuasca, 103
- basal ganglia  
 direct and indirect  
 pathways in, 13  
 neurochemical anatomy  
 of, 11  
 neuropeptides in, 13
- BH<sub>4</sub>  
 biosynthesis of  
 phenylalanine and  
 tyrosine, 6  
 brain concentration, 23, 24
- classical  
 phenylketonuria, 21  
 dopamine release, effect  
 on, 22, 24  
 Segawa's disease, 21  
 TH activity, affinity  
 regulation of, 22,  
 24, 25
- binding potential, definition  
 of, 108
- bipolar disorder  
 D<sub>2</sub>-like dopamine receptors  
 in, 200  
 FDOPA-PET in, 76
- blood brain barrier  
 export of acidic metabolites  
 through, 90–91  
 LNAA transport across, 6,  
 10, 55  
 P-glycoprotein in, 10
- γ-butyrolactone  
 brain dopamine  
 concentration  
 increased by, 128  
 TH activity decreased by, 33
- butyrophenones  
 first successful PET studies  
 of dopamine  
 receptors using, 18  
 invulnerability in most  
 psychostimulant  
 studies of, 185–186
- pharmacological specificity  
 and binding  
 properties, of,  
 174–175  
 vulnerability to Ecstasy  
 challenge of, 186
- Ca<sup>2+</sup>  
 concentration in interstitial  
 fluid, 125  
 MPTP and 6-OHDA toxicity,  
 role in, 12

- vesicular fusion, role in, 113
- Calcium, *see* Ca<sup>2+</sup>
- cannabis  
 COMT, and risk of psychosis, 83, 216  
 effects on D<sub>2</sub>-like dopamine receptors, 216
- Carlsson, Arvid  
 discovery of autoreceptor regulation of dopamine synthesis, 24  
 receives Nobel Prize in Medicine, 3  
 schematic model of catecholamine fibre, 5, 7
- catechol-O-methyltransferase, *see* COMT
- cerebellum, validity as reference tissue, 177
- c-fos expression  
 adrenal medulla and, 48  
 MAO-B knockout mice and, 103  
 stimulation of dopamine receptors and, 16, 164
- choreoathetosis, and [<sup>11</sup>C]DTBZ-PET, 121
- Cloninger, *see* personality and cognition, relation with
- cocaine  
 abuse of  
   D<sub>2</sub>-like dopamine receptors and, 204, 210–211  
   DAT-PET and, 157  
 blockade of DAT, 9  
 as a PET tracer, 141  
 rewarding properties, 16, 158
- interstitial dopamine levels and, 124, 126, 130  
 relation with impulsivity in rats and, 218
- coffee, effect on D<sub>2</sub>-receptor availability, 213
- cognition, *see* personality and cognition, relation with
- competition model in vivo  
 against D<sub>1</sub>-like receptors, failure to demonstrate, 173  
 D<sub>2</sub>-like receptors, and invulnerability of butyrophenone ligands, 185  
 labelled with antagonist ligands, 182, 184  
 particular vulnerability of agonist ligands, 185
- DAT imaging, 148
- MAO-PET, 110
- COMT  
 activity with respect to brain DOPA, 39  
 alleles, 83  
 D<sub>1</sub>-like dopamine receptor binding and, 172  
 distribution in brain, 82  
 enzyme biochemistry, 80  
 inhibition and inhibitors FDOPA-PET, 63  
 microdialysis studies, 93  
 target as antipsychotic treatment, 98  
 metabolism of plasma FDOPA by, 55  
 prolongation of DOPA therapeutic action by, 82
- concentration gradients for DOPAC between brain compartments, 123  
 dopamine across the plasma membrane, 127, 129  
 dopamine between vesicle and cytosolic space, 124  
 LNAA across BBB, 10
- cyclic nucleotides  
 phosphorylation of TH and, 25–26  
 regulation of AAADC and, 49
- D<sub>1</sub>-like dopamine receptor  
 absolute abundance of, 190–192, 227–228  
 agonists  
   claims for existence of distinct affinity states, 167  
   internalization evoked by, 165  
 PET ligands for, 168  
 signal transduction pathways of, 9, 16, 160, 163, 165
- D<sub>2</sub>-like dopamine receptor  
 absolute abundance of, 170, 227–228  
 agonists  
   dubious claims for existence of distinct affinity states, 167, 178, 213, 227, 233  
   internalization evoked by, 166  
 ligands for, 178–180  
 particular vulnerability in competition models, 185, 189, 192, 193

## 334 Index

- D<sub>2</sub>-like dopamine receptor (cont.)
- allelic variants
    - D<sub>2</sub>-like dopamine receptors and, 19
    - DAT-PET studies, 151
    - FDOPA-PET studies of, 75
  - butyrophenone ligands in vivo, 166, 175
  - D<sub>3</sub> receptors, 163, 177
  - high and low affinity
    - benzamide ligands
    - cortical binding sites measured by PET, 191, 200, 201
    - general aspects, 176–177, 194
    - vulnerability to psychostimulants, 184, 187
  - long and short, forms of, 161
  - occupancy by
    - agonists, 202
    - antipsychotics, 201
  - oligomeric associations of, 180
  - signal transduction
    - pathways of, 9, 16, 161, 163
  - upregulation in striatum after dopamine depletion, 181
  - receptor blockade, 203
- DAT
- density in brain, 145–146
  - extent of hemilesion and turning rate, 133, 138
  - knockout, and dopamine dynamics
    - behavioural effects, 140
  - dopamine dynamics measured by
    - electrochemistry, 126, 139
  - dopamine dynamics measured by microdialysis, 129
  - ligands for
    - [<sup>11</sup>C]cocaine, 141
    - molecular biology, 137, 151
    - Tropane ligands for SPET studies, 141–147
  - Parkinson's disease, 152–154
  - PET studies of aging, 149
- Dementia, *see* Alzheimer's dementia, and
- depolarization block
  - chronic antipsychotic treatment, 15
  - FDOPA PET study of, 70
- depression, *see* major depressive disorder
- dihydrotetraabenazine, *see* reserpine-like alkaloids
- dihydroxyphenylacetic acid, *see* acidic metabolites
- distribution volume
  - [<sup>11</sup>C]DTBZ, 118
  - [<sup>11</sup>C]harmine in pig brain, 108
- definition of, 41
- hungry chicken model of, 42
- DOPA
  - brain metabolism
    - compartmental model of, 51
    - multiple fates in living brain, or branching ratio, 7, 52
    - synthesis rate in rat striatum, 30, 31
  - effect in receptor competition models, 149
  - reanimation of reserpinized rabbits, 2
  - treatment for Parkinson's disease, 3
- DOPAC, *see* acidic metabolites
- DOPA decarboxylase, *see* AAADC
- dopamine
  - biosynthesis of, 6
  - concentration in interstitial fluid, 125
  - prediction error coding, and, 17
  - turnover, calculated from accumulation in rat striatum after pargyline, 87
  - conjugation by arylsulfotransferase, 81
  - decline in rat striatum after AMPT, 35, 86–88
  - fractional rate constant for breakdown by MAO, 87
  - washout of [<sup>18</sup>F] fluorodopamine in FDOPA-PET, 67
- dopamine D<sub>3</sub> or D<sub>4</sub> receptors, *see* D<sub>2</sub>-like dopamine receptor
- dopamine D<sub>5</sub> receptors, *see* D<sub>2</sub>-like dopamine receptor
- dopamine neurons
  - autoreceptors
    - apomorphine and, 27, 32
    - control of dopamine metabolism, 24

- discovery by Carlsson, 24
- possible contribution  
 to motor fluctuation  
 of Parkinson's  
 disease, 33
- postnatal development  
 of, 25
- size and abundance, 11, 12
- firing properties, and  
 depolarization  
 block, 15  
 reward, 17
- MPTP model of  
 parkinsonism, 72
- dopamine receptors,  
*see* D<sub>1</sub>-like dopamine  
 receptor, D<sub>2</sub>-like  
 dopamine receptor
- dopamine transporter, *see* DAT
- DOPA-responsive dystonia,  
*see* Segawa's disease
- dystonia, D<sub>2</sub>-like dopamine  
 receptors in, 198
- ecstasy, *see* MDMA, effect on  
 D<sub>2</sub>-like dopamine  
 receptor binding
- EEDQ and evidence for  
 receptor reserve, 168
- electrochemistry in vivo,  
 125–126
- estrogen, and dopamine  
 receptor binding, 179
- ethanol, effect on D<sub>2</sub>-like  
 dopamine receptor  
 availability, 213
- euphoria, *see* reward, relation  
 with dopamine  
 release
- extracellular fluid, *see*  
 interstitial fluid
- FDG, early application of  
 PET, 18
- FDOPA  
 clinical PET studies  
 aging, 71  
 MPTP model of  
 parkinsonism, 72  
 rate of progression  
 of Parkinson's  
 disease, 73  
 schizophrenia, 75,  
 76, 77  
 threshold for detection  
 of nigrostriatal  
 degeneration, 73  
 common partition volume  
 with LNAs in brain,  
 61, 63  
 quantitative PET methods  
 compartmental model of  
 metabolism, 55, 58,  
 63, 65  
 linear graphic analysis  
 with arterial input,  
 58, 60  
 linear graphic analysis  
 with reference tissue  
 input (Hartvig),  
 58–61  
 steady-state kinetics in  
 brain, 64, 66  
 studies of personality and  
 cognition, 78  
 time-activity curves in  
 monkey brain, 56  
 [<sup>18</sup>F]fluorodeoxyglucose,  
*see* FDG, early  
 application of PET  
 6-[<sup>18</sup>F]fluoro-L-DOPA,  
*see* FDOPA  
 6-[<sup>18</sup>F]fluoro-meta-  
 tyrosine, *see* FMT  
 feeding, and dopamine  
 release, 143, 221  
 fluordopamine, washout  
 from brain, 64, 67
- FMT  
 acquired parkinsonism in  
 monkeys, 72  
 alternate AAADC  
 substrate for PET  
 studies, 69  
 forskolin, and activation of  
 adenylate cyclase,  
 165
- GABA  
 effects of  $\gamma$ -vinyl-GABA on  
 [<sup>11</sup>C]raclopride  
 binding, 213  
 medium spiny neurons of  
 striatum, 13  
 gender differences  
 D<sub>2</sub>-like dopamine receptors  
 and amphetamine  
 challenge, 191,  
 195, 222  
 DAT binding, 151  
 FDOPA kinetics, 76  
 Gjedde-Patlak plot, *see* linear  
 graphic analysis
- G-proteins  
 association with  
 VMAT2, 114  
 control of TH activity, 32  
 lack of PET tracers for  
 signal transduction,  
 233
- haloperidol, *see* antipsychotic  
 medication, typical
- Hartvig plot, *see* FDOPA,  
 quantitative PET  
 methods
- heroin, *see* opiates
- high performance liquid  
 chromatography, *see*  
 HPLC
- homovanillic acid, *see* acidic  
 metabolites

## 336 Index

- HPLC  
 dopamine metabolites in  
 brain and interstitial  
 fluid, 93, 122  
 plasma metabolites  
 of PET tracers, 55,  
 104, 106
- Huntington's disease  
 D<sub>1</sub>-like dopamine  
 receptors, 172  
 D<sub>2</sub>-like dopamine  
 receptors, 198  
 DAT PET, 155  
 [<sup>11</sup>C]DTBZ-PET, 120  
 FDOPA-PET, 155
- HVA, *see* acidic metabolites
- 6-hydroxydopamine,  
*see* 6-OHDA
- interstitial fluid  
 behavioral correlates of  
 dopamine release,  
 131–132  
 dopamine concentration by  
 zero net flux  
 microdialysis  
 cortex, 140  
 striatum, 9, 124, 139  
 dopamine release  
 altered D<sub>2</sub>-like dopamine  
 receptor binding,  
 184  
 BH<sub>4</sub> effect on dopamine  
 release, 22  
 MAO inhibition, effect on  
 dopamine  
 metabolites, 93  
 precursor loading, and  
 effect on, 20, 25  
 unaltered D<sub>2</sub>-like  
 dopamine receptor  
 binding, 207, 214  
 microdialysis, general  
 aspects of, 123
- ketamine, *see* NMDA  
 antagonists
- large neutral amino acids,  
*see* LNAA carrier
- Lesch-Nyhan syndrome  
 DAT-PET, 155  
 FDOPA-PET, 75
- linear graphic analysis  
 applied to [<sup>11</sup>C]tyrosine  
 influx to monkey  
 brain, 42  
 applied to FDOPA  
 metabolite-corrected  
 arterial input,  
 58, 60  
 reference tissue input  
 method of Hartvig,  
 58–61
- linkage to dopamine  
 receptors, 9, 160, 228
- LNAA carrier  
 blood brain barrier, 6  
 countertransport of brain  
 OMD, 8  
 DOPA transport, 50  
 molecular biology of, 10
- locus ceruleus  
 Parkinson's disease,  
 degeneration in, 78  
 TH expression in, 29
- Logan plot  
 [<sup>11</sup>C]DTBZ binding, 118–119  
 [<sup>11</sup>C]harmine uptake, 107  
 benzamide binding, 176  
 bias, tendency for, 184
- LSD, competition against  
 dopamine D<sub>2</sub>-like  
 receptors, 215
- Machado-Joseph disease, *see*  
 spinocerebellar  
 ataxias, and DAT-  
 SPET
- major depressive disorder  
 D<sub>1</sub>-like dopamine  
 receptors, 171  
 D<sub>2</sub>-like dopamine  
 receptors, 211  
 DAT-PET, 156, 157  
 MAO-PET, 110
- MAO  
 activity with respect to  
 dopamine in vivo, 87  
 biochemistry, enzymology,  
 and substrate  
 specificity, 100  
 catabolism of dopamine,  
 8, 87  
 clinical PET studies of  
 depression, 110  
 epilepsy, 109  
 smoking, 109  
 knockouts and Norrie  
 Disease, 103  
 MPTP toxicity and  
 endogenous  
 Parkinson's disease,  
 103  
 neurochemical anatomy,  
 102  
 PET tracers  
 [<sup>11</sup>C]clorgyline, 106  
 [<sup>11</sup>C]deprenyl, difficulties  
 in kinetic modelling,  
 105  
 [<sup>11</sup>C]harmine, favourable  
 kinetics, 107  
 others, 109
- MAO inhibitors  
 AAADC activity, regulation  
 of, 48, 53  
 acidic metabolites,  
 turnover of, 93  
 D<sub>2</sub>-like dopamine  
 receptors, effect  
 on, 185  
 DAT binding, effects on, 57

- TH activity, regulation of, 32
- MDMA, effect on D<sub>2</sub>-like dopamine receptor binding, 189
- methamphetamine, *see* amphetamines
- methoxytyramine, *see* 3MT
- $\alpha$ -methyl-*para*-tryrosine, *see* AMPT
- methylphenidate  
 DAT-PET, tracer for, 148, 152, 158, 159  
 dopamine metabolites in striatal slices, 22  
 effects on benzamide binding, 184, 210  
 FDOPA utilization, effect of chronic treatment, 70  
 unmasks small binding changes in [<sup>11</sup>C]raclopride PET, 221
- microdialysis, *see* interstitial fluid
- monoamine neurons  
 revealed fluorescence histology, 2  
 TH immunohistochemistry, 11
- monoamine oxidase, *see* MAO
- monoamine vesicles, *see* vesicles
- movement and motor learning  
 availability of D<sub>2</sub>-like dopamine receptors, 195, 217, 222  
 interstitial dopamine release, 131–132
- MPTP  
 D<sub>1</sub>-like dopamine receptors, 167  
 D<sub>2</sub>-like dopamine receptors, 181
- DAT-PET and SPET studies  
 of, 146, 150, 152  
 [<sup>11</sup>C]DTBZ-PET studies of, 118, 119  
 FDOPA-PET studies of, 56–62, 72  
 model of Parkinson's disease, and toxicity for dopamine neurons, 12
- 3MT  
 forked path of dopamine metabolism, 6  
 kinetics in vivo, 93, 96  
 steady state concentrations in brain, 95
- NADPH diaphorase  
 patch-matrix compartments, 14  
 striatal interneurons, 11
- neurochemical anatomy  
 dopamine innervation, 13  
 dopamine neurons, 11  
 dopamine receptors, 161–162
- MAO, 102
- neuropeptide  
 coexpression, 13–15
- neuromelanin, and von Economo's encephalopathy, 3
- neuronal ceroid  
 lipofuscinosis
- D1-like dopamine receptors  
 binding, 172  
 FDOPA uptake, 75
- neuropeptides, coexpression  
 in striatal neurons, 13–15
- nicotine and smoking  
 D<sub>1</sub>-like dopamine receptors, 171  
 D<sub>2</sub>-like dopamine receptors  
 pharmacological challenge studies, 212–213, 221  
 possible relationship with tardive dyskinesia, 203  
 DAT-PET, 157  
 FDOPA-PET, 76  
 MAO-PET, 109  
 rewarding properties, 16, 130
- NMDA antagonists  
 AAADC activity, modulation by, 53, 214  
 D<sub>2</sub>-like dopamine receptor availability, effects on, 214
- NMSP, *see* butyrophenones
- Norrie disease, 103
- novelty seeking  
 personality, *see* personality and cognition, relation with
- NSD 1015  
 TH activity, assay of, 29  
 tryptophan hydroxylase activity, assay of, 31
- nucleus accumbens, and dopamine D<sub>3</sub> receptors, 162
- 6-OHDA  
 D<sub>2</sub>-like dopamine receptors, upregulation by, 181  
 detection of dopaminergic grafts, 143  
 interstitial dopamine concentration, 125  
 priming of response to agonists, 164

## 338 Index

- 6-OHDA (cont.)  
 Trojan horse toxicity  
   for dopamine neurons, 12  
   turning behaviour, 132, 138
- olivopontocerebellar atrophy,  
 [<sup>11</sup>C]DTBZ-PET findings, 120
- O-methyl-FDOPA,  
*see* OMF
- OMF  
 constrained  
   compartmental model for FDOPA, 63  
 formation in plasma from FDOPA, 55  
 subtraction of calculated brain concentrations, 66
- opiates  
 D<sub>2</sub>-like dopamine receptor availability, 214  
 interstitial dopamine, 131
- opioid receptors, distribution in patch matrix compartments, 14
- pain, and [<sup>11</sup>C]raclopride binding changes, 219
- pargyline, *see* MAO inhibitors
- Parkinson's disease  
 D<sub>1</sub>-like dopamine receptors, 170, 171  
 D<sub>2</sub>-like dopamine receptors  
   baseline levels, 191, 197  
   transcranial magnetic stimulation and deep brain stimulation, 216–217  
   treatment effects, 202, 211–212
- DAT-PET  
 evidence for  
   down-regulation of, 138, 152  
   studies of, 146, 152–154  
 FDOPA-PET studies of, 61, 62, 65, 72, 78  
 genetics and relationship with dopamine receptor alleles, 75  
 rate of progression of disease, 73, 74  
 washout of [<sup>18</sup>F]fluorodopamine, 67  
 [<sup>11</sup>C]DTBZ-PET studies of, 116, 120  
 HVA levels in CSF, 95  
 link with von Economo's encephalopathy, 2  
 motor fluctuations, possible effects of autoreceptors in, 33
- partial volume effects  
 AAADC activity measured by FDOPA-PET, 68  
 limited spatial resolution and, 230
- personality and cognition, relation with D<sub>2</sub>-like dopamine receptors, 195, 217  
 DAT binding sites, 151  
 FDOPA-PET, 77, 78
- PET  
 description of, 17  
 watch smashing, end of, 9
- phenylalanine, competitive inhibition of TH, 20
- phenylalanine hydroxylase  
 classical phenylketonuria, 21  
 inhibition by pPCA, 20
- synthesis of tyrosine in brain, 6
- phenylketonuria  
 biochemistry of, 21  
 FDOPA-PET, 62
- pheochromocytoma  
 AAADC in, 48  
 TH expression in, 27
- placebo, and dopamine competition paradigm, 223
- plasma metabolites of PET tracers  
 [<sup>11</sup>C]harmine, 107  
 FDOPA and [<sup>11</sup>C]DOPA, 54–56
- positron emission tomography, *see* PET
- prediction error, and dopamine signalling, 17
- probenecid, blockade of acidic metabolite transport, at BBB, 90, 92
- protein  
 precursor pool for brain tyrosine salvage, 40  
 synthesis in brain measured with [<sup>11</sup>C] tyrosine PET, 43
- protein kinases  
 D<sub>1</sub>-like receptor binding, 171  
 DAT, phosphorylation by, 137  
 TH, phosphorylation by, 26, 27
- raclopride, *see* antipsychotic medications, typical
- reserpine-like alkaloids  
 D<sub>1</sub>-like dopamine receptor binding, invulnerability to, 170, 173



- D<sub>2</sub>-like dopamine receptor  
 binding,  
 vulnerability to,  
 186–190  
 discovery of  
 antiparkinsonian  
 action of DOPA, 2  
 TH, activation by, 33  
 VMAT2  
 activation by, 114  
 PET ligands for,  
 115, 116  
 restless legs syndrome  
 D<sub>2</sub>-like receptor  
 availability, 198  
 FDOPA-PET, 75  
 reward, relation with  
 dopamine release,  
 16, 158, 159, 207,  
 213, 220–222
- S-adenosylmethionine, *see*  
 SAM, co-substrate for  
 COMT  
 SAM, co-substrate for COMT,  
 80, 81  
 schizophrenia  
 D<sub>1</sub>-like dopamine  
 receptor binding in,  
 168, 172  
 D<sub>2</sub>-like dopamine receptor  
 binding in  
 amphetamine challenge  
 paradigm, 205  
 controversy about, 192,  
 198–299  
 FDOPA-PET studies of, 62,  
 65, 76  
 [<sup>11</sup>C]DTBZ-PET, 121  
 DAT-PET, 155  
 depolarization block  
 after chronic  
 antipsychotic  
 medication, 15, 70
- steady-state FDOPA  
 trapping reduced  
 in, 77  
 washout of  
 [<sup>18</sup>F]fluorodopamine  
 increased in, 76  
 Segawa's disease  
 BH<sub>4</sub> synthesis and, 21  
 empty vesicles visualized  
 with [<sup>11</sup>C]DTBZ-PET,  
 120  
 self-administration,  
*see* reward, relation  
 with dopamine  
 release  
 serotonin  
 binding sites  
 cocaine action at, 140  
 biosynthesis, 31  
 D<sub>2</sub>-like dopamine receptor  
 availability,  
 modulation by, 215  
 antipsychotic  
 medication,  
 atypical, occupancy  
 by, 201  
 dopamine ligands,  
 cross-talk with,  
 141, 142, 169, 174,  
 203  
 neurons  
 DOPA metabolism  
 within, 50  
 TH activity, modulation by  
 agonists of, 34  
 sexual behaviour, and  
 dopamine release,  
 138  
 smoking, *see* nicotine and  
 smoking  
 spinocerebellar ataxias, and  
 DAT-SPET, 155  
 spiperone, *see*  
 butyrophenones
- stress  
 dopamine release evoked  
 by, 135, 220  
 striatum  
 interneurons, 15  
 patch-matrix  
 compartments,  
 13–14, 139  
 slices  
 methylphenidate-  
 evoked dopamine  
 overflow, 22  
 properties of, 123  
 substance P, *see*  
 neuropeptides  
 substantia nigra  
 dopamine neurons in,  
 11, 12  
 loss of pigmented neurons  
 in, 3  
 subthalamic stimulation,  
 lack of effect on  
 [<sup>11</sup>C]raclopride  
 binding, 216  
 synaptosomes  
 general properties  
 of, 123  
 TH activity in striatum,  
 20, 26  
 tetrahydrobiopterin, *see* BH<sub>4</sub>  
 TH  
 activity  
 assayed with intra-  
 cerebroventricular  
 [<sup>3</sup>H]tyrosine  
 infusion, 36  
 assayed with intravenous  
 [<sup>3</sup>H]tyrosine  
 injection, 36  
 assayed by NSD 1015  
 method, 29, 31  
 assayed by push-pull  
 cannula, 35

## 340 Index

- TH (cont.)  
 autoreceptor regulation  
 of, 7, 22, 24–26, 30,  
 32–33, 39, 44  
 PET study with  
 [<sup>11</sup>C]tyrosine, 41  
 pharmacological  
 modulation of, 34  
 biochemical properties of,  
 19, 23, 27  
 classical rate limiting step  
 for catecholamine  
 synthesis, 7, 22, 24  
 immunohistochemical  
 localization in  
 brain, 11  
 phenylalanine as a  
 substrate in  
 brain, 20  
 phosphorylation and  
 transcriptional  
 regulation, 25, 27  
 transgenic mice  
 overexpressing, 28  
 Tourette's syndrome, and  
 [<sup>11</sup>C]DTBZ- PET, 121  
 DAT imaging, 156  
 trace amines  
 synthesis in rat striatum, 47  
 turnover in rodent  
 brain, 88  
 vesicular amine storage,  
 111, 129
- transcranial magnetic  
 stimulation, effects  
 on [<sup>11</sup>C]raclopride  
 binding, 216–217
- tryptophan hydroxylase,  
 activity in striatum,  
 31
- Tyrosine  
 compartmental model of  
 metabolism, 37, 38  
 effects of loading on DOPA  
 synthesis, 25  
 formation in liver, 5  
 precursor for brain protein  
 synthesis, 7  
 unidirectional blood-brain  
 clearance, 39, 41, 43  
 tyrosine hydroxylase, *see* TH
- ventral tegmental area,  
*see* VTA neurons
- vesicles  
 capacitance change during  
 fusion of, 112  
 dopamine quanta, concept  
 of, 126, 128
- vesicular monoamine  
 transporter, *see*  
 VMAT1, VMAT2
- VMAT1  
 chromaffin granules, used  
 for studies of  
 exocytosis, 112
- dopamine concentration  
 gradient, 113  
 MPTP toxicity, resistance  
 to, imparted by, 111
- VMAT2  
 ATP, required for dopamine  
 gradient, 9  
 dopamine, storage via, 8  
 molecular biology and  
 knockouts, 111, 114  
 binding properties of  
 radioligands for,  
 115–117  
 kinetic modelling,  
 117–118  
 Parkinson's disease and  
 dementias,  
 decreased in, 120  
 PET studies with  
 [<sup>11</sup>C]DTBZ, 120
- von Economo's  
 encephalopathy, 3
- VTA neurons  
 autoreceptor regulation,  
 notably weak  
 in, 24, 33  
 burst firing of, 15  
 dopamine D<sub>3</sub> receptors  
 in, 162  
 precursor loading,  
 dependence on, 25  
 TH immunohistochemistry  
 of, 11